Company profile: NexGen Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of an animal health technology digital platform and prescription management ecosystem for large and exotic animals, offering access to veterinarians and wildlife handlers and integrating products, services, and a knowledge base. Portfolio includes parasite control injectables (LongRange, Noromectin), sedatives (XylaMed), antiparasitic powders (Fenbendazole), diuretics (Furosemide), and metronidazole oral suspensions.
Products and services
- LongRange (Eprinomectin) Extended-Release Injectable: Extended-release injectable delivers advanced parasite control for livestock and exotic animals, employing Eprinomectin for prolonged efficacy and offered in various volumes
- Metronidazole Oral Suspension: Oral suspension used to treat bacterial and parasitic infestations in companion and large animals, formulated for oral administration to diverse species
- Noromectin (Ivermectin) Sterile Solution Injection: Sterile parasiticide injection delivers comprehensive protection in cattle and swine, using Ivermectin to control parasites
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to NexGen Pharmaceuticals
Global Stem Cell Technology
HQ: Belgium
Website
- Description: Provider of state-of-the-art veterinary stem cell products developed and produced for horses and dogs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Global Stem Cell Technology company profile →
Focus Technology Group
HQ: United States
Website
- Description: Provider of data-driven solutions and services, offering supply chain data, marketing and sales force automation, analytics, reporting, supply chain activation, customer loyalty, and incentive management (SPIFs) for small and medium businesses and some of the world’s largest companies in animal health.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Focus Technology Group company profile →
PetMedix
HQ: United Kingdom
Website
- Description: Provider of development-stage veterinary biopharmaceutical therapies for pets, based in Cambridge, UK. Builds on more than 30 years of innovation in human drug development and applies science to develop therapies intended to keep pets healthier, happier, and for longer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PetMedix company profile →
Gallant
HQ: United States
Website
- Description: Provider of investigational stem cell and regenerative therapies for pets, including off-the-shelf uterine tissue-derived treatments for canine and feline conditions such as osteoarthritis, dry eye, and inflammatory bowel disease. Offers stem cell banking with collection, processing, and cryogenic storage via annual and monthly plans, coordinates with local veterinarians during spay/neuter, and conducts research and development and clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gallant company profile →
QScout
HQ: United States
Website
- Description: Provider of proprietary diagnostic technology for farm-animal disease detection, leveraging animals' immune response to detect and stage infections. Offers QScout MLD for quarter-level detection of subclinical mastitis in dairy cows; QScout BLD for chute-side health diagnostics in beef cattle to guide antibiotic use; QScout RLD for rapid patient-side WBC count and differential; and QScout Farm Lab for real-time MLD test data.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full QScout company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for NexGen Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to NexGen Pharmaceuticals
2.2 - Growth funds investing in similar companies to NexGen Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for NexGen Pharmaceuticals
4.2 - Public trading comparable groups for NexGen Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →